609 related articles for article (PubMed ID: 31196874)
1. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.
Murthy SK; Begum J; Benchimol EI; Bernstein CN; Kaplan GG; McCurdy JD; Singh H; Targownik L; Taljaard M
Gut; 2020 Feb; 69(2):274-282. PubMed ID: 31196874
[TBL] [Abstract][Full Text] [Related]
2. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009-2014.
Kirchgesner J; Lemaitre M; Rudnichi A; Racine A; Zureik M; Carbonnel F; Dray-Spira R
Aliment Pharmacol Ther; 2017 Jan; 45(1):37-49. PubMed ID: 27781286
[TBL] [Abstract][Full Text] [Related]
4. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
[TBL] [Abstract][Full Text] [Related]
5. Trends in hospitalization rates for inflammatory bowel disease in the United States.
Bewtra M; Su C; Lewis JD
Clin Gastroenterol Hepatol; 2007 May; 5(5):597-601. PubMed ID: 17382602
[TBL] [Abstract][Full Text] [Related]
6. Lower regional and temporal ultraviolet exposure is associated with increased rates and severity of inflammatory bowel disease hospitalisation.
Limketkai BN; Bayless TM; Brant SR; Hutfless SM
Aliment Pharmacol Ther; 2014 Sep; 40(5):508-17. PubMed ID: 24943863
[TBL] [Abstract][Full Text] [Related]
7. Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases: a single-center experience.
Park KT; Sin A; Wu M; Bass D; Bhattacharya J
Inflamm Bowel Dis; 2014 Jul; 20(7):1242-9. PubMed ID: 24846718
[TBL] [Abstract][Full Text] [Related]
8. The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease.
Ananthakrishnan AN; Sakuraba A; Barnes EL; Pekow J; Raffals L; Long MD; Sandler RS
Aliment Pharmacol Ther; 2017 Jul; 46(2):162-168. PubMed ID: 28470787
[TBL] [Abstract][Full Text] [Related]
9. Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study.
Bernstein CN; Nabalamba A
Am J Gastroenterol; 2006 Jan; 101(1):110-8. PubMed ID: 16405542
[TBL] [Abstract][Full Text] [Related]
10. Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark.
Burisch J; Jess T; Egeberg A
Clin Gastroenterol Hepatol; 2019 Dec; 17(13):2704-2712.e3. PubMed ID: 30936024
[TBL] [Abstract][Full Text] [Related]
11. Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab
Ylisaukko-Oja T; Torvinen S; Ventola H; Schmidt S; Herrala S; Kononoff J; Voutilainen M
Scand J Gastroenterol; 2019 Jun; 54(6):726-732. PubMed ID: 31203693
[No Abstract] [Full Text] [Related]
12. Healthcare Utilisation and Drug Treatment in a Large Cohort of Patients with Inflammatory Bowel Disease.
Cars T; Wettermark B; Löfberg R; Eriksson I; Sundström J; Lördal M
J Crohns Colitis; 2016 May; 10(5):556-65. PubMed ID: 26733406
[TBL] [Abstract][Full Text] [Related]
13. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.
Ljung T; Karlén P; Schmidt D; Hellström PM; Lapidus A; Janczewska I; Sjöqvist U; Löfberg R
Gut; 2004 Jun; 53(6):849-53. PubMed ID: 15138212
[TBL] [Abstract][Full Text] [Related]
14. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Tennakoon A; Zubieta AA; Coward S; Jones J; Kaplan GG; Kuenzig ME; Murthy SK; Nguyen GC; Peña-Sánchez JN
J Crohns Colitis; 2020 Oct; 14(10):1354-1363. PubMed ID: 32648579
[TBL] [Abstract][Full Text] [Related]
15. Nationwide temporal trends in incidence of hospitalization and surgical intestinal resection in pediatric inflammatory bowel diseases in the United States from 1997 to 2009.
Debruyn JC; Soon IS; Hubbard J; Wrobel I; Panaccione R; Kaplan GG
Inflamm Bowel Dis; 2013 Oct; 19(11):2423-32. PubMed ID: 23974991
[TBL] [Abstract][Full Text] [Related]
16. Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease.
Lindsay JO; Armuzzi A; Gisbert JP; Bokemeyer B; Peyrin-Biroulet L; Nguyen GC; Smyth M; Patel H
Dig Liver Dis; 2017 Oct; 49(10):1086-1091. PubMed ID: 28826571
[TBL] [Abstract][Full Text] [Related]
17. Sustained clinical benefit, improved quality of life, and reduced intestinal surgery from maintenance infliximab treatment in inflammatory bowel disease
Hossain A; Lördal M; Olsson AE; Storlåhls A; Aleman S; Eberhardson M; Befrits R
Scand J Gastroenterol; 2020 Feb; 55(2):178-183. PubMed ID: 32052663
[No Abstract] [Full Text] [Related]
18. Declining hospitalisation and surgical intervention rates in patients with Crohn's disease: a population-based cohort.
Rahman A; Jairath V; Feagan BG; Khanna R; Shariff SZ; Allen BN; Jenkyn KB; Vinden C; Jeyarajah J; Mosli M; Benchimol E
Aliment Pharmacol Ther; 2019 Nov; 50(10):1086-1093. PubMed ID: 31621934
[TBL] [Abstract][Full Text] [Related]
19. Do Thiopurines Reduce the Risk of Surgery in Elderly Onset Inflammatory Bowel Disease? A 20-Year National Population-Based Cohort Study.
Alexakis C; Saxena S; Chhaya V; Cecil E; Curcin V; Pollok R
Inflamm Bowel Dis; 2017 Apr; 23(4):672-680. PubMed ID: 28151735
[TBL] [Abstract][Full Text] [Related]
20. Long-term effectiveness and safety of anti-TNF in pediatric-onset inflammatory bowel diseases: A population-based study.
Fumery M; Dupont C; Ley D; Savoye G; Bertrand V; Guillon N; Wils P; Gower-Rousseau C; Sarter H; Turck D; Leroyer A
Dig Liver Dis; 2024 Jan; 56(1):21-28. PubMed ID: 37137808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
